



POSTER PRESENTATION

Open Access

# P85 - Asthmatic children and adolescents treated in daily medical practice – results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets

Efstrathios Karagiannis<sup>1\*</sup>, Kija Shah-Hosseini<sup>2</sup>, Meike Hadler<sup>1</sup>, Ralph Mösges<sup>2</sup>

From 3rd Pediatric Allergy and Asthma Meeting (PAAM)  
Athens, Greece. 17-19 October 2013

## Background

The aim of this non-interventional study was to document the impact of a sublingual allergen immunotherapy (AIT) with Oralair 5-grass pollen tablets (Stallergenes, France) on symptom severity (rhinitis, conjunctivitis, asthma), use of symptomatic medication and tolerability in patients with grass pollen-induced allergic rhinoconjunctivitis (RC) over 2 years of routine medical practice treatment. This poster focuses on the subgroup of asthmatic children (4-11 yrs) and adolescents (12-17 yrs).

## Methods

This prospective, open, non-controlled, non-interventional, multicenter study was conducted from September 2010 to October 2012 in Germany. Overall 1.482 patients (93 asthmatic children (6.2%), 73 asthmatic adolescents (4.9%)) participated in the study.

The patients rated their symptoms as a combined score of severity (scale: 0 [none] – 3 [severe]) and frequency (scale: 0 [none] – 4 [very often]). In the combined RC score, the severity of rhinitis and conjunctivitis were pooled (scale: 0 [none] – 6 [severe]). In the asthma score, the severity and the frequency were pooled (scale: 0 [none] – 7 [severe]).

## Results

During the season preceding AIT treatment 93/ 92% of children/ adolescents with asthma had used symptomatic medication for RC symptoms. This rate dropped

to 64/ 68% (1<sup>st</sup> season) and to 57/ 41% (2<sup>nd</sup> season). Likewise the RC score in these patients decreased from 4.06/ 4.13 to 1.86/ 1.82 (1<sup>st</sup> year) and to 1.33/ 1.59 (2<sup>nd</sup> year). Also the asthma score was reduced from 3.36/ 3.55 to 1.24/ 1.51 (1<sup>st</sup> year) to 0.71/ 1.13 (2<sup>nd</sup> year).

An improvement in health status after two years of treatment was documented by 96/ 96%.

Adverse events occurred in 19.4/ 17.8% over two years of treatment. The incidence of non-fatal serious adverse events was 3.2/ 0.0%.

At the end of the 2<sup>nd</sup> season, 96/ 96% evaluated the tolerability of the 5-grass pollen tablets as very good or good.

## Conclusion

Based on the study results, AIT with Oralair 5-grass pollen tablets was well tolerated by children and adolescents with asthma in routine medical practice. Symptomatic medication for RC symptoms use was significantly reduced. The asthma- and the RC score were also reduced significantly after one and two years under treatment with Oralair 5-grass pollen tablets compared to the season preceding AIT.

## Authors' details

<sup>1</sup>Stallergenes GmbH, Kamp-Lintfort, Germany. <sup>2</sup>Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University Hospital Cologne, Cologne, Germany.

<sup>1</sup>Stallergenes GmbH, Kamp-Lintfort, Germany  
Full list of author information is available at the end of the article

Published: 28 February 2014

doi:10.1186/2045-7022-4-S1-P140

**Cite this article as:** Karagiannis *et al.*: P85 - Asthmatic children and adolescents treated in daily medical practice – results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets. *Clinical and Translational Allergy* 2014 **4**(Suppl 1):P140.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

